EXOSENS PROM (EXENS) Fair Value & Analysis
Industrials · FR · Market cap €2.8B · ISIN FR001400Q9V2
What is EXOSENS PROM really worth?
Below-average quality, and trading another 212% above our fair value of €17.69.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price −12.7% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (€22.11). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (€10.98 to €22.11) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
27‑month range €16.97 – €72.57 · fair‑value band €10.98 – €22.11 · the €55.20 price screens above the €17.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
EXOSENS PROM (EXENS) currently trades at €55.20, while our model-based Fair Value estimate is €17.69, implying the stock looks roughly 212.0% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Industrials sector. Bull case: the Growth Earnings group reads highest at a median of €27.19 per share, and 0 of the 26 models we run sit above the €55.20 price. Bear case: the Asset-Based group reads lowest at €5.89, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, EXOSENS PROM generated revenue of €468M at a net margin of 9.1%. Revenue grew 20.1% year over year. It earns a return on equity of 16.4%. Net debt stands at €211M. Fundamentals as of Aug 13, 2026
Our scenario range runs from €10.98 (bear case) to €22.11 (bull case); at €55.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 25% below its 52-week high and 53% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at −44% fair-value upside, at −68%, EXENS screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly €0.2504 per share, which is 1.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings (€27.19) versus Dividend Discount (€1.52). Highest evidence: Residual Income (76).
Notify me when EXENS reaches fair value
Put EXENS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging.
Full company description
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and components, such as phosphor screens, resistive glass products, microchannel plates, and electron generator arrays. It also provides bare and energy compensated Geiger- Müller tubes; gamma and neutron detectors; mineral insulated extensions; and silicon photodiodes, as well as methane airborne detection solutions. The company sells its products under the Exosens, Photonis, Xenics, Telops, El-Mul, and Noxant brand names. It serves defense and surveillance, life sciences and environment, industrial control, and nuclear markets. The company was founded in 1937 and is headquartered in Mérignac, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EXOSENS PROM reported revenue of €468M in FY2025 versus €166M in FY2021, a compound +29.6%/yr. Reported net income was €42.7M in FY2025.
EXENS screens 212% overvalued. Compare with Contemporary Amperex Technology Co →
Peer Group
Electrical Equipment & Parts · 542 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Electrical Equipment & Parts median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Electrical Equipment & Parts stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Contemporary Amperex Technology Co 3750 | HK$652.50 | HK$394.19 | −40% |
| ABB Ltd ABBN | CHF 80.10 | CHF 28.70 | −64% |
| Delta Electronics (Thailand) Public Company TDED | 10.40 SGD | 1.47 SGD | −86% |
| Vertiv Holdings VRT | $257.08 | $63.13 | −75% |
| LG Energy Solution, Ltd 373220 | 365,500 KRW | 201,455 KRW | −45% |
| Prysmian S.p.A PRY | €117.10 | €84.15 | −28% |
| Legrand SA LR | €139.65 | €78.82 | −44% |
| Sungrow Power Supply Co 300274 | ¥86.40 | ¥123.83 | +43% |
| Hubbell Incorporated HUBB | $443.31 | $285.77 | −36% |
| Shenzhen Inovance Technology Co 300124 | ¥61.07 | ¥33.04 | −46% |
Compare EXOSENS PROM with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is EXOSENS PROM (EXENS) overvalued or undervalued?
What is the fair value of EXENS?
What is the quality score of EXENS?
What is the revenue of EXOSENS PROM (EXENS)?
What is the net profit margin of EXENS?
Does EXOSENS PROM pay a dividend?
Watch EXOSENS PROM in the live analysis
One click puts EXOSENS PROM on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.